SymbolSCLX
NameSCILEX HOLDING CO
SectorHEALTH CARE
RegionNorth America
IndustryBiological Products, (No Diagnostic Substances)
Address960 SAN ANTONIO ROAD, PALO ALTO, CA 94303
Telephone(650) 516-4310
Fax
Email
Websitehttps://www.scilexholding.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001820190
Description

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of neuropathic pain associated with post-herpetic neuralgia. We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYB, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. Our product candidates include SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA TM), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, SP-103 (lidocaine topical system) 5.

Additional info from NASDAQ:
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of neuropathic pain associated with post-herpetic neuralgia. We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYB, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. Our product candidates include SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA TM), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, SP-103 (lidocaine topical system) 5.

2026-07-08 01:25

SCLX Stock Acquisition JV LLC 🔴 sold 500.0K shares of Scilex Holding Co (SCLX) Transaction Date: Jul 03, 2026 | Filing ID: 297858

Read more
2026-07-07 22:28

New Form SCHEDULE 13D/A - Scilex Holding Co <b>Filed:</b> 2026-07-07 <b>AccNo:</b> 0001193125-26-297859 <b>Size:</b> 256 KB

Read more
2026-07-06 15:35

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026

Read more
2026-07-06 10:15

(10% Negative) SCILEX HOLDING CO (SCLX) Announces Business Combination

Read more
2026-07-06 10:00

Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

Read more
2026-06-29 21:01

(99% Neutral) SCILEX HOLDING CO (SCLXW) Announces Business Combination

Read more
2026-06-24 20:52

(99% Neutral) SCILEX HOLDING CO (SCLXW) Announces Regulatory Update

Read more
2026-06-16 11:45

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026

Read more
2026-06-12 11:45

Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

Read more
2026-06-12 07:03

New Form EFFECT - Scilex Holding Co <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 9999999995-26-001971 <b>Size:</b> 1 KB

Read more